<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">58</article-id><article-id pub-id-type="doi">10.15789/2220-7619-2011-3-271-274</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">ProMMP-1 PRODUCTION BY CULTIVATED CELLS OF VASCULAR ENDОTHELIUM IN VITRO AND IN A HUMAN BODY</article-title><trans-title-group xml:lang="ru"><trans-title>ПРОДУКЦИЯ проММП-1 КУЛЬТИВИРУЕМЫМИ КЛЕТКАМИ СОСУДИСТОГО ЭНДОТЕЛИЯ IN VITRO И В ОРГАНИЗМЕ ЧЕЛОВЕКА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Scliankina</surname><given-names>N. N.</given-names></name><name xml:lang="ru"><surname>Склянкина</surname><given-names>Н. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>scheglovitova@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Boldyreva</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Болдырева</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>scheglovitova@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Babayants</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Бабаянц</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>scheglovitova@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Frolova</surname><given-names>I. S.</given-names></name><name xml:lang="ru"><surname>Фролова</surname><given-names>И. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>scheglovitova@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Belyaev</surname><given-names>D. L.</given-names></name><name xml:lang="ru"><surname>Беляев</surname><given-names>Д. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>scheglovitova@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Portnova</surname><given-names>Yu. A.</given-names></name><name xml:lang="ru"><surname>Портнова</surname><given-names>Ю. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>scheglovitova@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Scheglovitova</surname><given-names>O. N.</given-names></name><name xml:lang="ru"><surname>Щегловитова</surname><given-names>О. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., профессор, зав. лабораторией противовирусного иммунитета</p><p>123098, Москва, ул. Гамалеи, 18</p></bio><email>scheglovitova@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ФГБУ «НИИЭМ им. Н.Ф. Гамалеи» Минздравсоцразвития России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2011-06-30" publication-format="electronic"><day>30</day><month>06</month><year>2011</year></pub-date><volume>1</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>271</fpage><lpage>274</lpage><history><date date-type="received" iso-8601-date="2014-06-30"><day>30</day><month>06</month><year>2014</year></date><date date-type="accepted" iso-8601-date="2014-06-30"><day>30</day><month>06</month><year>2014</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Scliankina N.N., Boldyreva N.V., Babayants A.A., Frolova I.S., Belyaev D.L., Portnova Y.A., Scheglovitova O.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, Склянкина Н.Н., Болдырева Н.В., Бабаянц А.А., Фролова И.С., Беляев Д.Л., Портнова Ю.А., Щегловитова О.Н.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Scliankina N.N., Boldyreva N.V., Babayants A.A., Frolova I.S., Belyaev D.L., Portnova Y.A., Scheglovitova O.N.</copyright-holder><copyright-holder xml:lang="ru">Склянкина Н.Н., Болдырева Н.В., Бабаянц А.А., Фролова И.С., Беляев Д.Л., Портнова Ю.А., Щегловитова О.Н.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/58">https://iimmun.ru/iimm/article/view/58</self-uri><abstract xml:lang="en"><p><bold>Abstract.</bold> Matrix metalloproteinases (MMP) are structurally related endopeptidase composed of active sites which include ions Zn2+ and Ca2+. Cultured cells of human blood vessels produce MMP-1, proteolytic effect is aimed at splitting the collagen I and III types, and subsequent vascular remodeling. MMP-1 is synthesized as an inactive zymogen proMMP-1. It was shown that interferon alpha, beta and gamma inhibited production by culture of HUVEC proenzyme MMP-1, which seems to characterize their anti-angiogenic action. The effect of immunomodulators is more difficult to explain: perhaps inhibiting effect of imunofan and, as well as activating effect of cycloferon due to their internal structural peculiarities. The action of interferon alpha, beta and gamma, used as HUVEC before infection with HSV-1, and after it led to decrease in production proMMP-1. Apparently, the antiangiogenic effect of IFN is saved in the case of infection of cultures of vascular endothelium with HSV-1. Scatter in the content of proMMP-1 in the serum of blood donors was 1.625–11.8 ng/ml and in patients with chronic microbial-viral infections was 1.22–21.16 ng/ml. Higher rates of proMMP-1 were in older patients group. To estimate the system of MMP in vitro, and in the body a comprehensive study must be conducted, including proMMP-1, the active form of proenzyme and specific inhibitor of MMP-1.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Резюме.</bold>Матриксные металлопротеиназы (ММП) — это структурно связанные эндопептидазы, в состав активных центров которых входят ионы Zn2+ и Ca2+. Культивируемые клетки эндотелия кровеносных сосудов человека продуцируют ММП-1, протеолитический эффект которой направлен на расщепление коллагена I и III типов и последующее ремоделирование сосудов. ММП-1 синтезируется в виде неактивного профермента проММП-1. Показано, что IFN альфа, бета и гамма тормозили продукцию культурой ЭКПВЧ профермента ММП-1, что, по-видимому, характеризует их антиангиогенное действие. Эффект иммуномодуляторов сложен для объяснения: возможно, ингибирующее действие имунофана, также так и активирующее действие циклоферона, связаны с особенностями их структур. Действие IFN альфа, бета и гамма, использованных как до инфицирования ЭКПВЧ ВПГ-1, так и после него приводило к уменьшению продукции проММП-1. Видимо, антиангиогенное действие IFN сохраняется и при инфицировании культур эндотелия сосудов ВПГ-1. Разброс в содержании проММП-1 в сыворотке крови доноров составлял 1,625–11,8 нг/мл и у больных хроническими микробно-вирусными инфекциями составлял 1,22–21,16 нг/мл. Более высокие показатели проММП-1 были у больных старшей возрастной группы. Для оценки работы системы ММП in vitro и в организме необходимо комплексное исследование, включающее проММП-1, активную форму профермента и специфический ингибитор ММП-1.</p></trans-abstract><kwd-group xml:lang="en"><kwd>proMMP-1</kwd><kwd>vascular endothelium</kwd><kwd>HUVEC</kwd><kwd>interferon</kwd><kwd>immunomodulators</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>проММП-1</kwd><kwd>эндотелий сосудов</kwd><kwd>ЭКПВЧ</kwd><kwd>интерферон</kwd><kwd>иммуномодуляторы</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1.	Соловьева Н.И. Матриксные металлопротеиназы: регуляция активности и роль в процессе онкогенеза // Вопр. мед. химии. — 2000. — № 5. — С. 30–31.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2.	Bellon G., Martiny L., Robiner A. Matrix metalloproteinases and matrikines in angiogenesis // Crit. Rev. Oncol. Haemathol. — 2004. — Vol. 49, N 3. — P. 203–220.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3.	Birkedal-Hansen H., Moore W.G., Bodden M.K., Windsor L.J., Birkedal-Hansen B., DeCarlo A., Engler J.A. Matrix metalloproteinases: review // Crit. Rev. Oral. Biol. Med. — 1993. — Vol. 4, N 2. — P. 197–250.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4.	De Wever O., Derycke L., Hendrix A., De Meerleer G., Godeau F., Depypere H., Bracke M. Soluble cadherins as cancer biomarkers // Clin. Exp. Metastasis. — 2007. — Vol. 24, N 8. — P. 685–697.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5.	Egeblad M., Werb Z. New function for the matrix metalloproteinases in cancer progression // Nat. Rev. Cancer. — 2002. — N 2. — P. 161–174.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.	Haas T.L. Endothelial cell regulation of matrix metalloproteinases // Can. J. Phisiol. Pharmacol. — 2005. — Vol. 83, N 1. — P. 1–7.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7.	Hayashida K., Bartlett A.H., Chen Y., Park P.W. Molecular and cellular machanisms of ectodomain shedding // Anat. Rec. — 2010. — Vol. 293, N 6. — P. 925–937.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8.	Heissig B., Hattori K., Friedrich M., Rafii S., Werb Z. Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases // Curr. Opin. Haemathol. — 2003. — Vol. 10, N 2. — P. 136–141.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9.	Malemud C.J. Matrix metalloproteinases (mmpS) in health and desease: overview // Front Biosci. — 2006. — N 11. — P. 1696–1701.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10.	Mott J.D., Werb Z. Regulation of matrix biology by matrix metalloproteinases // Curr. Opin. Cell Biol. — 2004. — Vol. 16, N 5. — P. 558–564.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11.	.Nagase H., Woessner J.F. Matrix metalloproteinases // J. Biol. Chem. — 1999. — Vol. 274, N 31. — P. 21491–21494.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12.	Ozato K., Taylor P., Kubota T. The interferon regulatory factor family in host defense: mechanism of action // J. Biol. Chem. — 2007. — Vol. 282, N 28. — P. 20065–20069.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13.	Parks W.S., Wilson C.L., Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity // Natl. Rev. Immunol. —2004. — Vol. 4, N 8. — P. 617–629.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14.	Scheglovitova O.N., Romanov Yu.A., Maksianina E.V., Kabaeva N.V., Pronin A.G. Herpes simplex type I virus infection of cultured human vascular endothelial cells: expression of cell adhesion molecules and induction of interferon and cytokine production by blood mononuclear cells // Russian J. Immunol. — 2001. — N 6. — P. 367–376.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15.	Woessner J. MMPs and TIMPs — an historical perspective // Mol. Biotechnol. — 2002. — Vol. 22, N 1. — P. 33–49.</mixed-citation></ref></ref-list></back></article>
